DRUG NAME: Cefuroxime

• First-generation (cefazolin IV, cephalexin oral) — excellent gram-positive (MSSA) + limited gram-negative
• Second-generation (cefuroxime IV/oral, cefaclor oral) — good gram-positive + enhanced gram-negative (particularly H. influenzae including beta-lactamase producers, M. catarrhalis)
• Third-generation (ceftriaxone IV, cefixime oral, cefpodoxime oral) — broader gram-negative + better CSF penetration; reduced gram-positive activity

• Community-acquired pneumonia (CAP)
• Acute otitis media (AOM) — extremely common in Indian children
• Acute bacterial sinusitis
• Acute exacerbation of COPD (AECOPD)

• It is a narrower-spectrum alternative to ceftriaxone for non-severe community-acquired infections where gram-negative coverage beyond first-generation is needed but third-generation breadth is unnecessary.
• Oral cefuroxime axetil is a reasonable alternative to oral cefixime for mild-moderate respiratory and urinary infections — with better gram-positive (MSSA, pneumococcal) coverage.
• Using cefuroxime when appropriate (instead of defaulting to ceftriaxone) preserves third-generation cephalosporin efficacy and reduces selection pressure for ESBL and AmpC resistance — a critical concern in Indian hospitals.

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Intravenous (IV) — slow IV injection (bolus) or intermittent IV infusion (as cefuroxime sodium)
• Intramuscular (IM) — deep IM injection (as cefuroxime sodium; acceptable alternative when IV access unavailable)
• Oral — tablets and dry syrup/suspension (as cefuroxime axetil — a prodrug)

---

Biosimilar Status:

---

Formulations Available in India

A. Parenteral Formulations — Cefuroxime Sodium

B. Oral Formulations — Cefuroxime Axetil (Prodrug)

C. Fixed-Dose Combinations (FDCs)

• Proponents argue: Clavulanic acid extends cefuroxime’s coverage to include some beta-lactamase-producing organisms that may be borderline resistant to cefuroxime alone.
• Opponents argue: Cefuroxime is ALREADY intrinsically stable against the common respiratory beta-lactamases (TEM-1, SHV-1 from H. influenzae, beta-lactamase from M. catarrhalis) — adding clavulanic acid provides minimal additional benefit for its labelled indications. The FDC adds cost, increases GI adverse effects (clavulanate-driven diarrhoea), and is not supported by major guidelines (ICMR, API Textbook, IDSA) as superior to cefuroxime alone for any standard indication.
• Current status: Available in the Indian market from some manufacturers. Not banned by CDSCO. Not included in NLEM. Indian prescribers should use cefuroxime axetil alone for standard indications — the addition of clavulanate is generally unnecessary. If broader beta-lactamase coverage is needed, amoxicillin-clavulanate (a well-validated FDC) is the preferred choice.

---

PHARMACOKINETICS

Parenteral (IV/IM) — Cefuroxime Sodium

Oral — Cefuroxime Axetil (Prodrug)

Common PK Parameters (Both Routes — After Cefuroxime Is in Systemic Circulation)

---

---

• IV cefuroxime sodium → Oral cefuroxime axetil (same drug, same spectrum)
• No need to change molecules for step-down
• Simplifies prescribing and reduces risk of spectrum mismatch during step-down
• This is a pharmacological advantage over: cefazolin (IV) → cephalexin (oral) = different molecule; ceftriaxone (IV) → cefixime (oral) = different generation with different spectrum

---

---

---

• If anaerobic coverage is needed (aspiration pneumonia, intra-abdominal, dental, bite wounds): → Amoxicillin-clavulanate is preferred (or cefuroxime + metronidazole).
• If enterococcal coverage is needed (UTI with suspected enterococci, peritonitis): → Amoxicillin-clavulanate or ampicillin-based regimen.
• If GI tolerability is a priority (history of antibiotic-associated diarrhoea, elderly): → Cefuroxime (lower diarrhoea rate than amoxicillin-clavulanate).
• If a single-agent IV-to-oral step-down without anaerobic/enterococcal needs: → Cefuroxime is a clean, efficient choice.
• If paediatric palatability matters: → Amoxicillin-clavulanate suspension is better tolerated than cefuroxime suspension (but cefixime or cefpodoxime suspensions are even better tolerated).

---

ADULT INDICATIONS + DOSING

• ⛔ MRSA infections (no activity)
• ⛔ ESBL-producing gram-negative infections (no activity — high prevalence in India)
• ⛔ Pseudomonas infections (no activity)
• ⛔ Gonorrhoea (resistance too high — use ceftriaxone per NACO/ICMR guidelines)
• ⛔ Meningitis as first-line (CSF penetration adequate but inferior to ceftriaxone — use ceftriaxone/cefotaxime)
• ⛔ Serious/life-threatening MSSA infections (use cefazolin or cloxacillin — better MSSA activity)
• ⛔ Anaerobic infections (no B. fragilis coverage — add metronidazole if anaerobic component)
• ⛔ Enterococcal infections (intrinsic resistance)

---

• Starting dose: Full therapeutic dose from first administration (no titration for antibiotics)
• Titration: Not applicable
• Usual maintenance dose: 750 mg IV q8h (parenteral); 250–500 mg oral q12h (oral)
• Maximum dose: Parenteral: Max 1.5 g per dose; Max 6 g per day (q6h). Oral: Max 500 mg per dose; Max 1 g per day.

---

Primary Indications (Approved / Standard in India)

---

Indication 1: COMMUNITY-ACQUIRED PNEUMONIA (CAP) — Non-Severe, Hospitalised or Outpatient

1. When to prefer cefuroxime over alternatives for CAP:
2. • ✅ When second-line oral therapy is needed (amoxicillin-clavulanate failure or intolerance): cefuroxime axetil oral provides equivalent respiratory pathogen coverage (S. pneumoniae, H. influenzae, M. catarrhalis) with potentially better GI tolerability (less diarrhoea than amoxicillin-clavulanate).
   • ✅ When IV-to-oral step-down within the same molecule is desired: cefuroxime sodium IV → cefuroxime axetil oral. Eliminates the spectrum uncertainty of cross-molecule step-down (e.g., ceftriaxone IV → cefixime oral = generation change with spectrum shift).
   • ✅ When an antimicrobial stewardship alternative to ceftriaxone is appropriate: for non-severe, community-acquired pneumonia WITHOUT risk factors for gram-negative MDR organisms, cefuroxime provides adequate coverage without the broader gram-negative pressure of third-generation cephalosporins.
3. When NOT to use cefuroxime for CAP:
4. • ⛔ Severe CAP (CURB-65 ≥3, ICU admission) — requires broader coverage (piperacillin-tazobactam, ceftriaxone, or carbapenem ± macrolide/fluoroquinolone).
   • ⛔ Suspected aspiration pneumonia — cefuroxime has NO anaerobic (Bacteroides) coverage. Use ampicillin-sulbactam, amoxicillin-clavulanate, or clindamycin + ceftriaxone.
   • ⛔ Hospital-acquired pneumonia (HAP) / VAP — likely MDR gram-negatives requiring broader agents.
   • ⛔ Suspected atypical pneumonia as monotherapy — cefuroxime does NOT cover Mycoplasma, Chlamydophila, Legionella. Must combine with macrolide or doxycycline, or use respiratory fluoroquinolone monotherapy.
   • ⛔ Penicillin-resistant pneumococcus (MIC >2 mg/L for penicillin) — cefuroxime MICs may be elevated. Use ceftriaxone or respiratory fluoroquinolone.
   • ⛔ Known or suspected ESBL-producing pathogen — cefuroxime is inactive.
5. NLEM India status: ✅ Cefuroxime injection (750 mg, 1.5 g) IS included in NLEM India 2022. Oral cefuroxime axetil is NOT separately NLEM-listed (but amoxicillin-clavulanate oral IS NLEM-listed as the preferred oral agent for respiratory infections).
6. Time to expected clinical response: Defervescence and symptom improvement within 48–72 hours. CRP should decline by >50% at day 3–4.
7. Treatment failure at 72 hours: Reassess: rule out complications (empyema, lung abscess), drug-resistant organism, atypical pathogen, non-infectious mimic (malignancy, TB, eosinophilic pneumonia). Obtain sputum culture. Consider broadening coverage (ceftriaxone + macrolide or respiratory fluoroquinolone). ⚠️ India-specific: Always consider tuberculosis in non-resolving pneumonia — obtain sputum for AFB smear and GeneXpert.
8. Baseline investigations: MANDATORY: Chest X-ray, SpO₂, allergy history. RECOMMENDED: CBC, CRP/procalcitonin, renal function (for cefuroxime dose adjustment if needed), blood cultures (if hospitalised), sputum Gram stain and culture.
9. Specialist initiation: Not required for non-severe outpatient CAP — primary care appropriate. Hospitalised CAP: physician/internist. ICU-level CAP: do NOT use cefuroxime.
10. Indian guideline source: API Textbook of Medicine (CAP chapter); ICMR Antimicrobial Treatment Guidelines 2019; Joint ICS-NCDC Guidelines for CAP. ℹ️ API Textbook lists cefuroxime as one of the parenteral beta-lactam options for hospitalised non-severe CAP alongside ampicillin-sulbactam and amoxicillin-clavulanate IV.
11. Key safety warning: ⚠️ Oral cefuroxime axetil must be taken WITH FOOD — if the patient reports taking it on an empty stomach, this may explain apparent treatment failure (subtherapeutic serum levels due to ~40–50% reduced absorption).
12. Dose adjustment: Renal impairment: extend interval per CrCl (see Part 3). Elderly: assess renal function. Obesity: standard doses generally adequate for non-severe CAP.

---

Indication 2: ACUTE OTITIS MEDIA (AOM) — Second-Line Therapy

1. When to prefer cefuroxime for AOM:
2. • ✅ Second-line after amoxicillin failure (no improvement at 48–72 hours on first-line amoxicillin 80–90 mg/kg/day). IAP Guidelines and API Textbook recommend amoxicillin-clavulanate OR oral cefuroxime axetil as second-line for AOM.
   • ✅ When amoxicillin is contraindicated (non-severe penicillin allergy — cefuroxime is a cephalosporin alternative with low cross-reactivity ~2–5%).
   • ✅ When beta-lactamase-producing H. influenzae is suspected (recurrent AOM, daycare attendance, recent antibiotic exposure).
3. When NOT to use:
4. • ⛔ NOT first-line for uncomplicated AOM — first-line is high-dose amoxicillin (80–90 mg/kg/day) per IAP and AAP guidelines. Cefuroxime is second-line.
   • ⛔ If compliance is a concern: cefuroxime axetil suspension has a notoriously bitter taste — poor palatability is a major barrier to paediatric adherence. If taste is an issue, cefpodoxime proxetil or cefdinir suspensions (better-tasting) may be preferred alternatives.
5. NLEM India: ✅ Injection is NLEM. Oral is NOT NLEM-listed (amoxicillin-clavulanate is NLEM for this indication).
6. Time to response: 48–72 hours. If no improvement → ENT referral, tympanocentesis for culture.
7. Indian guideline: IAP Guidelines on AOM; API Textbook.

---

Indication 3: ACUTE BACTERIAL SINUSITIS (ABS) — Second-Line Therapy

1. When to prefer: Second-line after amoxicillin or amoxicillin-clavulanate failure. Covers S. pneumoniae, H. influenzae (including beta-lactamase producers), M. catarrhalis — the three primary ABS pathogens.
2. When NOT to use: ⛔ NOT first-line — first-line is amoxicillin or amoxicillin-clavulanate per API Textbook and ICMR guidelines. ⛔ NOT for suspected fungal sinusitis, complicated sinusitis with intracranial extension, or nosocomial sinusitis (likely MDR organisms).
3. Diagnosis confirmation: Bacterial sinusitis requires: symptoms ≥10 days without improvement, OR worsening after initial improvement (“double sickening”), OR severe onset (high fever ≥39°C + purulent discharge ≥3 days). Do NOT prescribe cefuroxime for viral rhinosinusitis (the vast majority of cases).
4. NLEM India: ✅ Injection NLEM.
5. Indian guideline: API Textbook (ENT Infections chapter); ICMR Guidelines.

---

Indication 4: ACUTE EXACERBATION OF COPD (AECOPD) — Moderate Severity

1. When to prefer: AECOPD with at least 2 of 3 Anthonisen criteria (increased dyspnoea, increased sputum volume, increased sputum purulence) — especially if purulent sputum is present (strongest predictor of bacterial infection). Cefuroxime covers the three commonest AECOPD pathogens: H. influenzae, S. pneumoniae, M. catarrhalis. API Textbook and GOLD 2024 guidelines list cefuroxime as an appropriate oral/parenteral beta-lactam option.
2. When NOT to use: ⛔ NOT for mild AECOPD without purulent sputum (antibiotics unlikely to benefit). ⛔ NOT if Pseudomonas risk factors (frequent exacerbations, structural lung disease, recent hospitalisation, chronic systemic steroid use) — use antipseudomonal agent (piperacillin-tazobactam, cefepime). ⛔ NOT if ESBL gram-negative suspected.
3. NLEM India: ✅ Injection NLEM.
4. Indian guideline: API Textbook (COPD chapter); GOLD 2024.

---

Indication 5: URINARY TRACT INFECTIONS (UTI) — Complicated and Uncomplicated

5A: Uncomplicated Lower UTI (Acute Cystitis)

5B: Complicated UTI / Acute Pyelonephritis

1. When to prefer cefuroxime for UTI:
2. • ✅ When urine culture confirms a susceptible, non-ESBL organism (E. coli, Proteus, Klebsiella — non-ESBL).
   • ✅ As an alternative to amoxicillin-clavulanate when the latter is not tolerated (GI side effects).
   • ⚠️ Cefuroxime is NOT first-line for uncomplicated cystitis. Preferred first-line per ICMR guidelines: nitrofurantoin 100 mg BD × 5 days or fosfomycin 3 g single dose.
3. ⚠️ CRITICAL India-specific limitation — ESBL prevalence:
4. • ESBL prevalence among Indian uropathogens: 40–70% in hospital-acquired UTIs; 20–40% in community-acquired UTIs in urban India.
   • Cefuroxime is COMPLETELY INEFFECTIVE against ESBL producers.
   • ⚠️ Always obtain urine culture and sensitivity BEFORE starting cefuroxime for UTI — especially in India. If culture returns ESBL: switch immediately (nitrofurantoin for lower UTI; carbapenem or piperacillin-tazobactam for complicated/upper UTI).
5. NLEM India: ✅ Injection NLEM.
6. Baseline investigations: MANDATORY: Urine routine + culture-sensitivity before starting. Renal function (dose adjustment if CrCl <30).
7. Indian guideline: ICMR AMR Treatment Guidelines 2019; API Textbook.

---

Indication 6: SKIN AND SOFT TISSUE INFECTIONS (SSTIs) — Mild to Moderate

1. When to prefer: Mild-moderate community-acquired SSTIs (cellulitis, wound infection, impetigo requiring systemic therapy) where both staphylococcal AND streptococcal coverage is needed but the infection is NOT severe enough for IV antistaphylococcal penicillin or cefazolin.
2. When NOT to use:
3. • ⛔ MRSA SSTI — cefuroxime is inactive. Use cotrimoxazole, doxycycline, clindamycin, or vancomycin.
   • ⛔ Serious/deep MSSA infections (bacteraemia, endocarditis, osteomyelitis) — cefuroxime has LESS anti-MSSA potency than first-generation cephalosporins (cefazolin) or antistaphylococcal penicillins (cloxacillin). For serious MSSA infections: use cefazolin or cloxacillin.
   • ⛔ Polymicrobial SSTIs (bite wounds, diabetic foot, perianal) — need anaerobic coverage (add metronidazole or use amoxicillin-clavulanate/ampicillin-sulbactam).
   • ⛔ Necrotising fasciitis — surgical emergency + broad-spectrum IV antibiotics.
4. NLEM India: ✅ Injection NLEM.
5. Indian guideline: API Textbook; ICMR AMR Guidelines; IADVL Guidelines.

---

Indication 7: SURGICAL PROPHYLAXIS — Select Procedures

Procedures where cefuroxime prophylaxis is used in India:

1. Cefazolin vs Cefuroxime for surgical prophylaxis — which to choose?
2. • Cefazolin is the globally preferred first-line prophylactic agent for most clean and clean-contaminated surgeries: longer half-life (q4h re-dosing vs q3–4h for cefuroxime), superior MSSA coverage, better-established weight-based dosing (2 g standard; 3 g for ≥120 kg), NLEM-listed, and most Indian surgical prophylaxis protocols list cefazolin as first-line.
   • Cefuroxime is a valid alternative — particularly favoured in some UK-influenced protocols (NICE). Its advantage: slightly broader gram-negative coverage (especially H. influenzae) which may be marginally beneficial for procedures involving mucosal surfaces (head & neck, ENT, dental) where H. influenzae colonisation is relevant.
   • In Indian practice: Most Indian surgical prophylaxis protocols (AIIMS, NCDC) list cefazolin as first-line with cefuroxime as an acceptable alternative. Either is reasonable.
3. ⚠️ Re-dosing interval is SHORTER for cefuroxime than cefazolin: Cefuroxime half-life (~1.5 hrs) < cefazolin half-life (~2 hrs) → re-dose at 3–4 hours intraoperatively (vs q4h for cefazolin). Failure to re-dose in long procedures is a common prophylaxis failure.
4. ⛔ Do NOT continue prophylaxis >24 hours — same antimicrobial stewardship principle as cefazolin.
5. NLEM India: ✅ Cefuroxime injection (750 mg, 1.5 g) IS NLEM-listed.
6. Indian guideline: AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines; ASHP/IDSA/SIS Surgical Prophylaxis Guidelines 2013 (adapted for Indian practice).

---

Indication 8: EARLY LYME DISEASE (Erythema Migrans) — Oral Therapy

1. Context for Indian practice: Lyme disease (caused by Borrelia burgdorferi sensu lato) is uncommon in India but has been reported in forested/hilly regions — Himalayan states (Himachal Pradesh, Uttarakhand, Jammu & Kashmir), northeast India (Assam, Meghalaya, Manipur), and parts of Western Ghats. Indian clinicians in these regions should be aware of Lyme disease in patients with tick exposure + erythema migrans rash.
2. Drug of choice: First-line for early Lyme disease (erythema migrans without neurological or cardiac involvement): Doxycycline 100 mg oral BD × 14–21 days (also covers co-infections; contraindicated in children <8 years and pregnancy). Cefuroxime axetil and amoxicillin are alternatives — particularly when doxycycline is contraindicated (children <8 years, pregnancy).
3. NLEM India: ✅ Injection NLEM. Not specifically listed for Lyme indication (disease is rare in India).
4. Indian guideline: Limited Indian Lyme disease guidelines. API Textbook mentions Lyme disease. IDSA/AAN/ACR Lyme Disease Guidelines 2020 used internationally.

---

Secondary Indications — Adults Only (Off-label, if any)

---

Off-Label Indication 1: INTRACAMERAL CEFUROXIME — Endophthalmitis Prophylaxis After Cataract Surgery

• 💡 This is one of the most impactful antimicrobial prophylaxis interventions in modern ophthalmology. The landmark ESCRS Endophthalmitis Study (Barry et al., J Cataract Refract Surg, 2006; European multicentre RCT, n=16,603) demonstrated that intracameral cefuroxime reduced post-cataract endophthalmitis rates by approximately 5-fold (from ~0.35% to ~0.07%) compared to no intracameral injection.
• ⚠️ Preparation is CRITICAL — dilution errors can cause retinal toxicity. The standard cefuroxime sodium injection vial (750 mg or 1.5 g) must be diluted meticulously to achieve the final concentration of 10 mg/mL, from which 0.1 mL is drawn (= 1 mg). Overdosing (>1 mg) can cause toxic anterior segment syndrome (TASS) or macular oedema. Underdosing provides no prophylaxis. Many Indian ophthalmology centres now use pre-diluted, pharmacy-prepared aliquots or commercially available intracameral cefuroxime preparations (e.g., Aprokam — available in some international markets; availability in India may be limited — most centres prepare from standard IV vials under aseptic conditions).
• ⚠️ Specialist only — ophthalmologist administration in a sterile OT environment. NOT for general prescribing.
• ℹ️ India-specific: Cataract surgery is the most commonly performed surgical procedure in India (millions of procedures annually through government and private programmes). Post-operative endophthalmitis, though rare (~0.04–0.2%), is a devastating complication causing blindness. Adoption of intracameral cefuroxime prophylaxis in Indian ophthalmology is increasing but not yet universal. Barriers include: concern about dilution errors, cost, perceived medicolegal risk of off-label use, and availability of pre-prepared formulations. AIOS (All India Ophthalmological Society) has endorsed intracameral cefuroxime prophylaxis.
• Evidence basis:Strong — ESCRS RCT (2006); multiple confirmatory observational studies and meta-analyses; ESCRS Guidelines for Prevention of Endophthalmitis After Cataract Surgery (2013); AIOS endorsement.

---

Off-Label Indication 2: GONORRHOEA — NO LONGER RECOMMENDED

---

Off-Label Indication 3: PERIOPERATIVE PROPHYLAXIS — Intracameral (Eye Surgery) + Topical Drops

---

PAEDIATRIC DOSING (Specialist Only)

---

• Safety monitoring: Monitor for allergic reactions (rash, urticaria, anaphylaxis — rare), diarrhoea (common with oral cefuroxime axetil), and GI intolerance (nausea, vomiting — common). Renal function monitoring if prolonged course or concurrent nephrotoxic drugs.
• Minimum age: No specific lower age limit — used from the neonatal period onwards under specialist supervision (see neonatal section). Commonly prescribed from ≥3 months of age for standard paediatric indications.
• Formulation suitability:
• • Oral suspension (cefuroxime axetil 125 mg/5 mL): Available but with a MAJOR palatability problem. ⚠️ Cefuroxime axetil suspension has one of the WORST tastes among commonly prescribed paediatric oral antibiotics — intensely bitter, difficult to mask even with flavouring. This is a well-recognised barrier to paediatric compliance. Many Indian paediatricians avoid cefuroxime suspension specifically because of taste issues, preferring cefpodoxime proxetil or cefixime suspension (both better-tasting) for paediatric use.
  • Tablets (125 mg, 250 mg, 500 mg): Film-coated — suitable for older children who can swallow tablets whole. ⛔ Do NOT crush (extremely bitter + may reduce bioavailability).
  • IV/IM injection: Reconstituted from vials for weight-based paediatric dosing.
• Palatability — THE major paediatric prescribing issue:
• • If taste is a barrier and the child refuses cefuroxime suspension: switch to amoxicillin-clavulanate (better taste, similar spectrum), cefpodoxime proxetil (palatable suspension, similar respiratory coverage), or cefixime (palatable, good gram-negative coverage but weaker gram-positive).
  • Practical tips: mix the measured dose with a small amount of chocolate syrup or honey (for children >1 year) immediately before administration. DO NOT mix into a bottle of milk/formula (if child doesn’t finish, dose is incomplete).
• Age-specific PK: Neonates: prolonged half-life (~3–5 hours) — extended intervals. Infants >3 months: standard weight-based dosing adequate.
• Adolescent transition: Children ≥12 years or ≥40 kg → use adult dosing.

---

PAEDIATRIC DOSING REFERENCE TABLE

PARENTERAL (Cefuroxime Sodium):

ORAL (Cefuroxime Axetil — WITH FOOD):

---

Primary Indications — Paediatric (Approved / Standard in India)

---

Paediatric Indication 1: ACUTE OTITIS MEDIA (AOM) — Second-Line

• ⚠️ NOT first-line. First-line for AOM: high-dose amoxicillin (80–90 mg/kg/day divided q8–12h) per IAP Guidelines and API Textbook.
• Cefuroxime is second-line for: (a) amoxicillin failure at 48–72 hours; (b) amoxicillin allergy (non-severe penicillin allergy); © recurrent AOM with suspected beta-lactamase-producing H. influenzae.
• ⚠️ Palatability barrier: Cefuroxime axetil suspension is very bitter. If child refuses: switch to amoxicillin-clavulanate (preferred second-line per IAP) or cefpodoxime proxetil suspension (better taste).
• IAP Guidelines on AOM; API Textbook.
• NLEM: ✅ (injection).

---

Paediatric Indication 2: ACUTE BACTERIAL SINUSITIS — Second-Line

• Second-line after amoxicillin/amoxicillin-clavulanate failure.
• Same palatability concerns as AOM.
• Same first-line preferences (amoxicillin-clavulanate per IAP/API).

---

Paediatric Indication 3: COMMUNITY-ACQUIRED PNEUMONIA — Paediatric, Hospitalised

• ℹ️ For hospitalised paediatric CAP, first-line per IAP and WHO is IV ampicillin (or IV benzylpenicillin for confirmed pneumococcal pneumonia). Cefuroxime is used when: broader gram-negative coverage needed (H. influenzae), first-line failure, or non-severe penicillin allergy.
• Combine with macrolide (azithromycin 10 mg/kg/day OD × 5 days) if atypical pneumonia suspected (children >5 years).
• ⚠️ India-specific: Always consider TB in non-resolving paediatric pneumonia.
• IAP Guidelines on Paediatric Pneumonia; WHO Pneumonia Guidelines.
• NLEM: ✅ (injection).

---

Paediatric Indication 4: URINARY TRACT INFECTIONS — Paediatric

• Obtain urine C&S before starting — MANDATORY.
• ⚠️ ESBL prevalence in paediatric uropathogens rising in India — cefuroxime may be unreliable empirically.
• All children with first febrile UTI: renal ultrasound recommended. DMSA/MCU per IAP Paediatric Nephrology guidelines.
• NLEM: ✅ (injection).
• IAP Guidelines for UTI in Children.

---

Paediatric Indication 5: SKIN AND SOFT TISSUE INFECTIONS — Paediatric, Mild-Moderate

• For community-acquired paediatric SSTI (cellulitis, impetigo requiring systemic therapy).
• ⛔ NOT for MRSA SSTI (use cotrimoxazole or clindamycin).
• ⛔ NOT for bite wounds as monotherapy (add metronidazole for anaerobic coverage or use amoxicillin-clavulanate).
• Oral step-down to cefuroxime axetil or cephalexin (better taste for children).
• NLEM: ✅ (injection).

---

Paediatric Indication 6: SURGICAL PROPHYLAXIS — Paediatric

• Same principles as adult prophylaxis. Cefazolin is generally preferred; cefuroxime is an acceptable alternative.
• For paediatric colorectal/GI procedures: add metronidazole 7.5 mg/kg IV.
• IAP Guidelines; AIIMS Paediatric Surgery Protocol.
• NLEM: ✅ (injection).

---

Neonatal Dosing

1. ⛔ Cefuroxime is NOT first-line for empiric neonatal sepsis. Standard empiric EONS therapy per NNF India / AIIMS: Ampicillin + Gentamicin. Cefuroxime has NO activity against Listeria monocytogenes (all cephalosporins are intrinsically resistant to Listeria) or Enterococcus — both important EONS pathogens.
2. When cefuroxime IS used in neonates:
3. • Targeted therapy for culture-confirmed susceptible gram-negative organisms (after initial empiric regimen)
   • Surgical prophylaxis for neonatal surgery (cardiac, abdominal)
   • NOT as empiric first-line
4. ⛔ No oral formulation suitable for neonates. IV cefuroxime throughout neonatal treatment course. Oral step-down only post-neonatal period with cephalexin or cefuroxime axetil suspension.

---

Secondary Indications — Paediatric (Off-label, if any)

---

Off-Label Paediatric Indication 1: EARLY LYME DISEASE — Children

• For children <8 years (where doxycycline is contraindicated) with early Lyme disease (erythema migrans).
• Alternative: amoxicillin 50 mg/kg/day divided q8h × 14–21 days (preferred by many paediatricians due to better taste and bioavailability).
• ⚠️ Palatability: cefuroxime axetil suspension is very bitter — may be difficult for young children.
• Evidence basis:Moderate — IDSA/AAN/ACR Lyme Disease Guidelines 2020 list cefuroxime as a recommended alternative oral agent for early Lyme. Limited paediatric RCTs.
• Relevance in India: limited to Himalayan and northeast states.

---

Off-Label Paediatric Indication 2: PHARYNGOTONSILLITIS (GAS) — Alternative in Penicillin Allergy

• ℹ️ First-line for GAS pharyngitis: Penicillin V (250 mg BD–TDS × 10 days for children ≥12 years; 125–250 mg BD–TDS for younger children) or Amoxicillin (50 mg/kg/day divided BD–TDS × 10 days). Cefuroxime is an alternative for non-severe penicillin allergy.
• ⚠️ India-specific — Rheumatic fever prevention: India has one of the world’s highest burdens of rheumatic heart disease (RHD). Complete 10-day GAS pharyngitis treatment is CRITICAL for primary prevention of acute rheumatic fever. Shorter courses with any antibiotic are NOT acceptable for GAS pharyngitis in the Indian context — the prevention of rheumatic fever mandates full 10-day eradication therapy.
• Evidence basis:Strong — Multiple RCTs support cephalosporins (including cefuroxime) for GAS pharyngitis. AHA/IDSA Pharyngitis Guidelines; IAP Guidelines.

---

Off-Label Paediatric Indication 3: PERIORBITAL (PRESEPTAL) CELLULITIS — Mild-Moderate

• Cefuroxime provides coverage against S. aureus (MSSA), Streptococcus spp., AND H. influenzae — the three main preseptal cellulitis pathogens.
• ⚠️ CRITICAL: Differentiate preseptal from orbital cellulitis. Orbital cellulitis: proptosis, EOM restriction, visual changes → CT orbit + broader IV coverage + ophthalmology + ENT referral.
• Amoxicillin-clavulanate or ampicillin-sulbactam are more commonly used empirically (also cover anaerobes from sinusitis extension).
• Evidence basis:Weak — expert opinion, case series.

---

Paediatric Secondary Indications Summary Table

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

For Parenteral (IV/IM) — q8h Dosing (Hospital Setting)

• Doses administered by nursing staff on a fixed q8h schedule (e.g., 06:00, 14:00, 22:00).
• If delayed <4 hours: Administer immediately. Re-space subsequent doses to maintain q8h intervals from the delayed dose.
• If delayed >4 hours: Administer immediately. Inform treating physician. Resume regular q8h schedule from the delayed dose timing.
• ⚠️ For critically ill patients or those with serious infections (bacteraemia, severe pneumonia): If delay exceeds 2 hours, inform the treating physician — even a 2-hour gap with cefuroxime’s ~1.5-hour half-life means serum levels may have fallen to near-subtherapeutic.
• Never skip a dose entirely without physician instruction.

For Parenteral — q6h Dosing (Maximum/Severe Infections)

• If delayed <3 hours: Administer immediately. Re-space.
• If delayed >3 hours: Administer immediately, inform physician, resume schedule from delayed dose.

For Oral (Cefuroxime Axetil) — q12h Dosing (Outpatient)

• If remembered within 6 hours of the scheduled time: Take the missed dose immediately WITH FOOD. Then resume regular q12h schedule.
• If more than 6 hours late (i.e., next dose due within 6 hours): Skip the missed dose. Take the next dose at its scheduled time WITH FOOD. Do NOT double the dose.
• Never take two doses at once.

• Suggested schedule linked to meals: Morning dose with breakfast; Evening dose with dinner — leverages the mandatory “take with food” instruction to create a natural dosing anchor tied to meal times.
• This meal-linked schedule is easy for patients to remember and ensures both the q12h interval AND the food requirement are met simultaneously.

• Pre-operative dose missed: If recognised before incision → give immediately (even if within <30 minutes of incision — some tissue levels are better than none). If recognised after incision → give ASAP — late prophylaxis provides some benefit though suboptimal. Document the timing error.
• Intraoperative re-dosing missed: If the procedure exceeded 3–4 hours and re-dosing was not given → administer immediately upon recognition. If only recognised at the end of surgery → give as a post-operative dose.

• Cefuroxime is used as a finite-duration antibiotic course (typically 5–14 days). Not chronic therapy.
• If 2 or more consecutive oral doses are missed:
• • Sub-therapeutic levels will have been present for ≥24 hours → bacterial regrowth risk.
  • Resume immediately at full dose WITH FOOD — no re-titration needed.
  • Extend total course duration by the number of missed days.
  • If treating a serious infection (pyelonephritis, pneumonia) and multiple doses missed → reassess clinically, consider repeat cultures, and evaluate whether the missed doses have compromised treatment response.
• No withdrawal syndrome or rebound effect.
• No immunogenicity risk (not a biologic).

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

A. INTRAVENOUS ADMINISTRATION — Cefuroxime Sodium

• Batch pre-preparation of cefuroxime doses is less feasible than with cefazolin
• For OPAT: pre-prepared cefuroxime syringes/mini-bags have a shorter usable window than cefazolin — limiting home-based IV therapy logistics
• In Indian hospitals: reconstitute immediately before each dose is the safest practice, especially in hot climates where room temperature stability may be reduced

• Cefuroxime vials are typically single-use (no preservative).
• ⛔ Do NOT re-puncture repeatedly — contamination risk.
• For paediatric use where multiple small doses are drawn from one vial: use within the stated stability window, document reconstitution time, strict aseptic technique.
• In neonatal settings: use single-dose vials (preservative-free) only.

• Dose = 30 mg/kg × 15 kg = 450 mg per dose
• Using 750 mg vial reconstituted in 6 mL SWFI → concentration ~113 mg/mL
• Volume to draw = 450 mg ÷ 113 mg/mL = ~4 mL
• Dilute in 25–50 mL Normal Saline; infuse over 15–30 minutes.
• Or: administer 4 mL as slow IV push over 3–5 minutes.

• Dose = 25 mg/kg × 3 kg = 75 mg per dose
• Using 750 mg vial reconstituted in 6 mL → ~113 mg/mL
• Volume to draw = 75 mg ÷ 113 mg/mL = ~0.66 mL
• Dilute in 5–10 mL Normal Saline; infuse over 15–30 minutes using syringe pump.
• ⚠️ Use a 1 mL syringe for neonatal dosing accuracy.

---

B. INTRAMUSCULAR ADMINISTRATION — Cefuroxime Sodium

---

C. ORAL ADMINISTRATION — Cefuroxime Axetil

---

D. Storage Summary

E. Cold-Chain Guidance

• Cefuroxime dry powder (vials, tablets, dry syrup) does NOT require cold-chain storage. Stable at room temperature up to 30°C.
• After reconstitution (IV solution or oral suspension): refrigeration extends stability — recommended in Indian climates.
• No special transport cold-chain requirements for dry formulations.
• ℹ️ Indian context: Cefuroxime’s room-temperature stability for dry formulations makes it suitable for supply to PHCs, CHCs, and remote areas without cold-chain infrastructure — unlike some reconstituted biologics or temperature-sensitive drugs.

---

RENAL ADJUSTMENT

---

Adult Renal Dosing — Oral (Cefuroxime Axetil)

Paediatric Renal Adjustment

• ARC (CrCl >130 mL/min) can significantly increase cefuroxime clearance → subtherapeutic levels with standard q8h dosing.
• Common in: young adults with sepsis, polytrauma, burns, neurosurgical patients.
• Action in ARC:
• 1. Increase frequency: 1.5 g IV q6h (instead of q8h) — or use maximum dose q6h.
  2. Consider continuous infusion strategy (total daily dose in 24-hour NS infusion — specialist ICU protocol).
  3. If available: TDM to confirm adequate free drug concentrations (rarely available for cefuroxime in India).

---

HEPATIC ADJUSTMENT

---

• Anti-TB drugs (rifampicin, isoniazid, pyrazinamide): no additive liver risk from cefuroxime
• Methotrexate: no hepatic interaction from cefuroxime (though possible renal competition — see Drug Interactions)
• Valproate: no hepatic interaction
• Antiretrovirals: no hepatic interaction
• Paracetamol: no hepatic interaction

---

CONTRAINDICATIONS

---

⛔ Absolute contraindications — the drug must NEVER be used:

---

• Rationale: Risk of recurrent IgE-mediated anaphylaxis — potentially fatal. Includes documented angioedema, severe urticaria with hypotension, laryngospasm, or bronchospasm to any cephalosporin.
• ℹ️ Mild, delayed, non-IgE-mediated reactions to other cephalosporins (maculopapular rash without systemic features) are NOT absolute contraindications to cefuroxime but require cautious use with monitoring.

---

• ⛔ Avoid cefuroxime. Other cephalosporins with different side chains may be usable after formal allergy evaluation.
• Use alternative antibiotics: azithromycin (for respiratory infections), fluoroquinolone (levofloxacin/moxifloxacin for CAP), cotrimoxazole (for UTI), or vancomycin (for MSSA if all beta-lactams contraindicated).

---

CAUTIONS

---

⚠️ High-Priority Cautions

---

• Cefuroxime is ~85–95% renally eliminated. Dose interval extension is necessary when CrCl <20 mL/min (parenteral) or <30 mL/min (oral — conservative approach).
• Monitoring: Serum creatinine at baseline and periodically. Calculate CrCl before prescribing — especially in elderly Indian patients where “normal” creatinine may mask CKD.
• See Renal Adjustment table above.

---

• Cefuroxime is ~50% removed by standard HD. Post-HD supplemental dose MANDATORY.
• Failure to supplement → subtherapeutic levels for the post-HD period → treatment failure.

---

• ⚠️ This is clinically critical and is one of the most commonly overlooked prescribing instructions. Failure to take with food → ~40–50% reduction in bioavailability → subtherapeutic levels → treatment failure → unnecessary escalation to broader-spectrum agents.
• Monitoring: If a patient on oral cefuroxime is not responding at 48–72 hours → FIRST ask: “Are you taking it with food?” before concluding treatment failure.

---

• ⚠️ In Indian hospital settings, ESBL prevalence is 40–70% among E. coli and Klebsiella. Cefuroxime is COMPLETELY INEFFECTIVE against ESBL producers.
• Action: Always obtain cultures before empiric use for UTIs and gram-negative infections. If ESBL confirmed: switch immediately (nitrofurantoin for lower UTI, carbapenem or piperacillin-tazobactam for complicated UTI/systemic infections).

---

• Cross-reactivity ~2–5%. For non-severe allergy: can use with monitored first dose. For severe anaphylaxis: formal allergy evaluation or alternative agent.
• See cross-reactivity table under Contraindications.

---

• All cephalosporins carry CDI risk. Second-generation cephalosporins (cefuroxime) carry LOWER CDI risk than third-generation cephalosporins (ceftriaxone — one of the highest-risk antibiotics for CDI). This is a stewardship advantage of using cefuroxime instead of ceftriaxone when the narrower spectrum is adequate.
• ⚠️ Nevertheless, CDI can occur — especially in elderly, hospitalised, PPI-using, recently antibiotic-treated patients.
• Monitoring: Report new-onset watery diarrhoea. Test for C. difficile toxin if suspected. Use shortest effective course.

---

• ⛔ Same stewardship principle as cefazolin — do NOT continue prophylaxis >24 hours post-operatively. No evidence of benefit; increases AMR and CDI risk.

---

• ⚠️ For intracameral cefuroxime (endophthalmitis prophylaxis after cataract surgery): the dose is 1 mg in 0.1 mL — a 1000-fold dilution from the standard 750 mg vial. Dilution errors can cause toxic anterior segment syndrome (TASS) or retinal toxicity at higher doses, or prophylaxis failure at lower doses.
• ⚠️ Specialist ophthalmology use ONLY. Must follow the precise dilution protocol (see Part 2). Use a 1 mL tuberculin syringe. Prepare fresh for each patient. Pre-prepared commercially available intracameral formulations (if available) reduce dilution error risk.

---

Standard Cautions

---

• Oral candidiasis, vaginal candidiasis, antibiotic-associated diarrhoea — standard antibiotic caution. Risk lower than with third-generation cephalosporins (narrower spectrum = less flora disruption).

---

• Very high-dose cephalosporins in renal impairment can rarely lower seizure threshold. Risk with cefuroxime at standard doses is very low. Adjust dose per renal function.

---

• False-positive urine glucose: With copper-reduction methods (Benedict’s test, Clinitest). ✅ Enzymatic methods (glucose oxidase — glucometer strips) are NOT affected.
• False-positive direct Coombs test (DAT): Possible — may complicate crossmatching. Clinical haemolysis is very rare.
• Interference with ferricyanide-based glucose assays: Cefuroxime can cause false LOW blood glucose readings with some point-of-care glucose monitoring systems that use the dehydrogenase-pyrroloquinoline quinone (GDH-PQQ) method. ⚠️ In hospitalised patients receiving IV cefuroxime: verify that the ward glucometer uses a glucose oxidase-based or GDH-FAD/GDH-NAD-based test strip (NOT GDH-PQQ). This is particularly relevant in Indian ICUs where multiple glucometer brands are used.

---

• ⚠️ Cefuroxime axetil oral suspension has one of the worst tastes among commonly prescribed paediatric antibiotics — intensely bitter. This is a well-recognised clinical problem leading to:
• • Refusal/spitting out the medicine → incomplete dosing → treatment failure
  • Vomiting immediately after administration → lost dose
  • Caregiver frustration → premature discontinuation
• Action: If compliance is an issue: switch to a better-tasting alternative (amoxicillin-clavulanate, cefpodoxime proxetil, cefixime, or — for gram-positive-only infections — cephalexin). Document the taste issue as the reason for switching.

---

• Extended dosing intervals (q8–12h) due to renal immaturity. NICU supervision required.
• ⛔ NOT for empiric neonatal sepsis (no Listeria or enterococcal coverage).

---

• Cefuroxime sodium contains approximately 2.4 mEq sodium per gram. At maximum dosing (6 g/day → ~14 mEq sodium/day from drug alone). In sodium-restricted patients (heart failure, cirrhosis): factor into total sodium budget. Generally clinically insignificant at standard doses.

---

• ⛔ Do NOT use cefuroxime for gonorrhoea — gonococcal resistance to cefuroxime is widespread in India and globally. Use ceftriaxone per NACO/ICMR guidelines. This is listed under Cautions (not Contraindications) because it is a treatment failure risk rather than a safety risk — but the clinical consequence (untreated gonorrhoea with complications) is serious.

---

• Film-coated tablets must be swallowed whole. Crushing releases intensely bitter taste → vomiting/refusal + potential bioavailability reduction. If patient cannot swallow tablets: use oral suspension formulation or switch to IV cefuroxime.

---

PREGNANCY

---

Trimester-Specific Risk Assessment

Key Obstetric Uses

Preferred Alternatives in Indian Obstetric Practice

Monitoring During Pregnancy

• Mother: Standard adverse effect monitoring. Renal function (pregnancy increases GFR — relevant for cefuroxime clearance but standard doses adequate). No LFT monitoring needed (zero hepatic metabolism/hepatotoxicity).
• Fetus/Neonate: No specific fetal monitoring required for standard courses. No known fetal toxicity.

---

LACTATION

---

Monitoring in Breastfed Infant

• Loose stools or mild diarrhoea (most common — transient)
• Nappy rash
• Oral thrush (uncommon)
• Skin rash or allergic reaction (very rare)

• ℹ️ For IV cefuroxime: dosing schedule is fixed by nursing staff. Breastfeed at any time. For oral cefuroxime axetil: take WITH food (meal time); breastfeed at any time. Timing relative to doses is NOT critical given the very low RID.

---

ELDERLY

---

Extra Risks Specific to Elderly

Common Clinical Scenarios in Elderly Indian Patients

---

MAJOR DRUG INTERACTIONS

---

---

Major Food-Drug and Herb-Drug Interactions

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

Paediatric-Specific Common ADR

---

SERIOUS ADVERSE EFFECTS

---

Antidote / Reversal Information

• Skin rash with blisters, peeling, or sores in mouth/eyes/genitals
• Swelling of face, lips, tongue, throat; difficulty breathing
• Severe watery or bloody diarrhoea with cramps and fever
• Reduced urine output or blood in urine
• Unusual bruising or bleeding
• For patients after eye surgery receiving this medicine in the eye: severe eye pain, redness, or sudden worsening of vision"

---

MONITORING REQUIREMENTS

---

Baseline (Before Starting)

---

After Initiation / Dose Change

---

Long-Term / Maintenance Monitoring

---

Therapeutic Drug Monitoring (TDM)

• ICU patients with augmented renal clearance (ARC) — to confirm adequate levels with q6h dosing
• Patients with severe renal impairment on dialysis — to confirm neither accumulation nor underdosing
• Morbid obesity — if clinical response is poor despite standard dosing

• No universally established therapeutic range. Key PK/PD target: free drug concentration above MIC for ≥40–50% of the dosing interval (%fT > MIC). For most susceptible organisms (MIC ≤ 4 mg/mL), standard dosing achieves this target.

• The antibiotic course is completed
• For courses ≤7 days in patients with normal renal function: no repeat monitoring necessary unless clinical concern

---

---

PATIENT COUNSELLING

---

---

• ⚠️ “ALWAYS take this medicine WITH FOOD — with breakfast and dinner (or with a meal/snack). This medicine works MUCH BETTER when taken with food. If you take it on an empty stomach, your body will absorb only half the medicine — and the infection may not clear.”
• “Take the tablet twice a day — once in the morning with breakfast and once in the evening with dinner.”
• “Swallow the tablet whole with a glass of water. Do NOT crush, break, or chew the tablet — it has a very bitter taste inside.”
• “Take your doses at regular times — about 12 hours apart (for example: 8 AM with breakfast and 8 PM with dinner).”
• “Complete the full course as prescribed by your doctor, even if you feel better before the course is finished. Stopping early can allow the infection to come back, and the germs may become resistant.”

• “Shake the bottle well before each dose.”
• “Use the measuring cup or oral syringe given with the bottle — do NOT use a household spoon (it gives the wrong amount).”
• ⚠️ “Give with food or immediately after a meal.”
• ℹ️ “This liquid has a bitter taste. Your child may not like it. You can try: (a) giving a small piece of chocolate or a sip of juice immediately after the medicine; (b) mixing the measured dose with a very small amount of chocolate syrup or honey (only for children over 1 year old) immediately before giving — but make sure the child takes ALL of the mixture. Do NOT mix into a full bottle of milk — if the child does not finish the bottle, the dose will be incomplete.”
• “If your child vomits within 30 minutes of taking the medicine, give the same dose again. If vomiting happens after 30 minutes, do NOT repeat — the medicine has already been absorbed.”
• “If your child keeps refusing or vomiting the medicine because of the taste, call your doctor — they may switch to a different medicine that tastes better.”

---

• “If you remember within 6 hours of the missed time, take the dose immediately with food. Then continue your regular schedule.”
• “If more than 6 hours have passed (that is, your next dose is due in less than 6 hours), skip the missed dose and take the next one at its normal time with food.”
• “Never take two doses at the same time to make up for a missed dose.”

---

• “You may get loose stools or mild diarrhoea — this is common and usually mild. Drink plenty of fluids (water, ORS, coconut water, buttermilk/chaas). If the diarrhoea is very severe, watery, bloody, or lasts more than 2 days, see your doctor.”
• “You may feel mild nausea or stomach discomfort — taking the medicine with food (as instructed) helps reduce this.”
• “The injection form may cause pain at the drip site (vein) — tell the nurse if you notice redness, swelling, or pain at the drip site.”

---

• ⚠️ “Difficulty breathing, swelling of the face/lips/tongue/throat, or feeling like your throat is closing — this could be a serious allergic reaction. Go to the nearest hospital immediately.”
• ⚠️ “Severe skin rash with blisters, peeling skin, or sores in the mouth/eyes — stop the medicine and go to hospital.”
• ⚠️ “Severe diarrhoea (bloody or very watery, many times a day) with fever and stomach cramps — see your doctor urgently. This can happen even up to 2 months after you finish the course.”
• ⚠️ “Yellow colour of the eyes or skin (jaundice) — very rare with this medicine, but see your doctor.”
• ⚠️ “Unusual bruising or bleeding — see your doctor.”
• ⚠️ “For patients who had eye surgery and received this medicine in the eye: severe eye pain, redness, cloudiness, or sudden loss of vision — contact your eye doctor immediately.”

---

• “Do NOT take this medicine on an empty stomach — always take with food.”
• “Do NOT crush the tablet — it is very bitter.”
• “There is no specific restriction on alcohol, but alcohol may worsen nausea and stomach discomfort. It is best to avoid alcohol while you are unwell with an infection.”
• “Do not take antacid medicines (like Digene, Gelusil, etc.) at the same time as this tablet — take the antacid at least 1 hour before or 2 hours after this medicine.”
• “Do not take any other medicines (including medicines bought from the chemist without prescription, and any Ayurvedic or herbal medicines) without telling your doctor.”

---

• Tablets: “Store at room temperature in a cool, dry place. Keep away from moisture and direct sunlight. Keep out of reach of children.”
• Reconstituted oral suspension (liquid): “Store in the fridge after the chemist adds water. If you do not have a fridge, keep it in the coolest part of your house (away from the kitchen, stove, and sunlight). Use within 10 days. Throw away any leftover liquid after 10 days.”
• ℹ️ Indian hot climate note: “In summer, the liquid medicine may spoil faster if left at room temperature. Try to keep it cool. If the liquid looks or smells different from when you first got it, do not use it — get a new bottle.”

---

• “This medicine is for a specific course to treat your infection — it is NOT a long-term medicine.”
• “Your doctor will tell you how many days to take it (usually 5–14 days). Please complete the full course.”
• “Do NOT stop early even if you feel better — the infection may come back and be harder to treat.”

---

• “Come back to your doctor if you are not feeling better after 3 days of taking this medicine.”
• “Come back for any blood tests or check-ups your doctor has asked for.”
• “If you had a urine infection, your doctor may ask for a repeat urine test after finishing the course to confirm the infection is gone.”

---

---

• ✔ Most important instruction: ALWAYS give with food (tablet or syrup). This is different from many other medicines that are taken on an empty stomach. For this medicine, food is essential — it helps the body absorb the medicine properly.
• ✔ How to give the correct dose — use the measuring cup or syringe provided, NOT a household spoon.
• ✔ Timing — twice a day, 12 hours apart, linked to meals (breakfast + dinner).
• ✔ For liquid: shake well. Store in fridge. Discard after 10 days.
• ✔ Swallow tablets whole — do NOT crush.
• ✔ Warning signs to watch for: difficulty breathing, swelling of face, severe rash/blisters, severe diarrhoea, reduced urine output, confusion. Bring to hospital immediately if any of these occur.
• ✔ Complete the full course — even if the child/patient seems well.
• ✔ Do NOT share this antibiotic with another family member or save leftover doses for future illness.

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

Parenteral — Cefuroxime Sodium (Injection):

Oral — Cefuroxime Axetil:

---

Estimated Per-Course / Per-Month Cost:

---

---

CLINICAL PEARLS

---

---

VERSION

---

REFERENCES

1. CDSCO Product Insert — Cefuroxime Sodium for Injection and Cefuroxime Axetil Tablets (multiple manufacturers; representative inserts from GlaxoSmithKline Pharmaceuticals India Ltd [Ceftum] and Abbott India Ltd [Supacef]). CDSCO-approved labelling for indications, dosing, contraindications, adverse effects, pharmacokinetics.
2. Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Monographs: Cefuroxime Sodium, Cefuroxime Axetil. Drug standards, identification, assay.
3. National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Cefuroxime injection (750 mg, 1.5 g) listed under Section 6.2 (Antibacterials — Beta-lactam medicines). Oral cefuroxime axetil is NOT separately NLEM-listed.
4. National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Cefuroxime monograph: indications, dosing, adverse effects, pharmacokinetics, renal adjustment.
5. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection for CAP, UTI, SSTI, AOM, sinusitis, and AECOPD. Resistance data for Indian pathogens. Antimicrobial stewardship recommendations. Reference for ESBL prevalence data in Indian uropathogens and respiratory pathogens.
6. API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Community-Acquired Pneumonia, Acute Otitis Media, Acute Bacterial Sinusitis, COPD Exacerbations, Urinary Tract Infections, Skin and Soft Tissue Infections, Surgical Site Infection Prevention, Lyme Disease.
7. IAP (Indian Academy of Pediatrics) Guidelines:
8. • IAP Guidelines on Management of Acute Otitis Media in Children (revised edition).
   • IAP Guidelines on Paediatric Community-Acquired Pneumonia (revised 2021).
   • IAP Guidelines on Urinary Tract Infections in Children.
   • IAP Guidelines on Antimicrobial Stewardship in Paediatrics.
9. NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management (latest edition). Referenced for neonatal dosing intervals and the recommendation that cefuroxime is NOT first-line for empiric neonatal sepsis.
10. WHO Pocket Book of Hospital Care for Children, 2nd Edition (2013) — World Health Organization. Paediatric dosing references, pneumonia management guidelines.
11. FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines — Caesarean section prophylaxis, UTI in pregnancy management.
12. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology of cefuroxime, mechanism of action, PK/PD of beta-lactams, spectrum of activity, cephalosporin classification, prodrug pharmacokinetics of cefuroxime axetil, food effect data.
13. Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Pneumonia, UTI, SSTI, Surgical Prophylaxis, Lyme Disease, Otitis Media, Sinusitis, COPD.
14. AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: Surgical prophylaxis protocols (orthopaedic, cardiac, general surgery), empirical pneumonia management, antimicrobial stewardship framework.
15. NCDC (National Centre for Disease Control) Infection Control Guidelines — Referenced for surgical prophylaxis recommendations in Indian hospital settings.
16. ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013) — Bratzler DW, et al. Am J Health-Syst Pharm; 70:195–283. Referenced for surgical prophylaxis indications, timing, re-dosing intervals, and duration. Adapted for Indian practice.
17. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery (2013) — European Society of Cataract and Refractive Surgeons. Referenced for intracameral cefuroxime prophylaxis evidence, dilution protocol, and ESCRS RCT (Barry P, et al. J Cataract Refract Surg 2006; 32:407–410).
18. GOLD 2024 — Global Initiative for Chronic Obstructive Lung Disease Report — Referenced for AECOPD antibiotic indications and cefuroxime positioning.
19. IDSA/AAN/ACR Lyme Disease Guidelines (2020) — Lantos PM, et al. Clin Infect Dis; 72:e1–e48. Referenced for cefuroxime axetil as alternative oral therapy for early Lyme disease.
20. NACO (National AIDS Control Organisation) / ICMR National Treatment Guidelines for Gonorrhoea — Referenced for the recommendation that cefuroxime should NOT be used for gonorrhoea due to widespread resistance; ceftriaxone is current first-line.
21. NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Ceiling price notifications for cefuroxime injection formulations. Available at nppaindia.nic.in.
22. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue and pricing. Available at janaushadhi.gov.in.
23. CDSCO Banned Drugs List — Gazette of India notifications on banned/restricted fixed-dose combinations. Reviewed to confirm no cefuroxime single-ingredient or approved FDC ban status.
24. PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in. Helpline: 1800-180-3024.
25. AIOS (All India Ophthalmological Society) — Endorsement of intracameral cefuroxime for post-cataract endophthalmitis prophylaxis. Referenced for Indian ophthalmology practice context.
26. Indian Paediatric Nephrology Group (IPNG) Guidelines — UTI management and investigation protocols in children. Referenced for paediatric UTI imaging recommendations.

---